![Francesca Chiodi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Francesca Chiodi
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMED AB
![]() IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Direttore/Membro del Consiglio | 26/11/2009 | - |
Fondatore | 26/11/2009 | - |
Storia della carriera di Francesca Chiodi
Statistiche
Distribuzione geografica
Svezia | 2 |
Posizioni
Director/Board Member | 1 |
Founder | 1 |
Settori
Retail Trade | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
IMED AB
![]() IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
- Borsa valori
- Insiders
- Francesca Chiodi
- Esperienza